Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

NCT ID: NCT01260168

Last Updated: 2015-05-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

435 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-10-31

Study Completion Date

2013-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to confirm the sensitivity of a stool DNA test for detection of colorectal cancer and pre-cancer.

Another objective is to provide anonymous, clinically characterized specimens for a bio-repository for future colorectal cancer-related test development.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients who have been recently diagnosed with colo-rectal cancer or pre-cancer will be asked to submit a stool sample(s)(at least 7 days AFTER colonoscopy) and will have the option of submitting blood and tissue samples for future colo-rectal cancer-related test development.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Neoplasms Digestive System Diseases Colonic Diseases Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Colorectal cancer patients

Subjects will be men and women, 40-90 years of age, inclusive, each with a colonoscopic biopsy-based diagnosis of colorectal cancer (CRC) and/or an intact pre-malignant colorectal lesion large enough to require surgical excision or complex colonoscopic polypectomy.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is male or female, 40-90 years of age, inclusive.
2. Subject has a diagnosis of CRC, at any stage, confirmed with a tissue biopsy and/or ≥1 cm colorectal polyp/adenoma/mass identified on a colonoscopy that is of sufficient size to require surgical excision or complex colonoscopic polypectomy.
3. Subject understands the study procedures and is able to provide informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.

Exclusion Criteria

1. Subject has active synchronous extra-colonic aerodigestive tract cancers (e.g., lung, esophagus, stomach, or pancreatic cancer).
2. Subject has a history of any inflammatory bowel disease.
3. Subject has familial adenomatous polyposis, hereditary non-polyposis colorectal cancer (Lynch) syndrome, or other hereditary cancer syndromes.
4. Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.
Minimum Eligible Age

40 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Exact Sciences Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Graham Lidgard, PhD

Role: STUDY_CHAIR

Chief Scientific Officer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Achieve Clinical Research, LLC

Birmingham, Alabama, United States

Site Status

Clinical Research Associates

Huntsville, Alabama, United States

Site Status

Atlanta Gastroenterology

Atlanta, Georgia, United States

Site Status

Jesse Brown VA

Chicago, Illinois, United States

Site Status

Rush University Gastroenterologists

Chicago, Illinois, United States

Site Status

Stroger Cook County

Chicago, Illinois, United States

Site Status

University of Illinois at Chicago

Chicago, Illinois, United States

Site Status

Rockford Gastroenterology Associates, Ltd

Rockford, Illinois, United States

Site Status

Gastroenterology Associates

Baton Rouge, Louisiana, United States

Site Status

Chevy Chase Clinical Research

Chevy Chase, Maryland, United States

Site Status

Commonwealth Clinical Studies

Brockton, Massachusetts, United States

Site Status

Long Island Gastrointestinal Group

Great Neck, New York, United States

Site Status

Mount Sinai School of Medicine

New York, New York, United States

Site Status

Asheville Gastroenterology

Asheville, North Carolina, United States

Site Status

Southern Gastroenterology Associates

New Bern, North Carolina, United States

Site Status

Northwest Gastroenterology Clinic, LLC

Portland, Oregon, United States

Site Status

Gastro One

Germantown, Tennessee, United States

Site Status

Digestive Health Specialists

Tyler, Texas, United States

Site Status

University of Utah

Salt Lake City, Utah, United States

Site Status

Digestive and Liver Disease Specialists

Norfolk, Virginia, United States

Site Status

University of Calgary

Calgary, Alberta, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

References

Explore related publications, articles, or registry entries linked to this study.

Lidgard GP, Domanico MJ, Bruinsma JJ, Light J, Gagrat ZD, Oldham-Haltom RL, Fourrier KD, Allawi H, Yab TC, Taylor WR, Simonson JA, Devens M, Heigh RI, Ahlquist DA, Berger BM. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol. 2013 Oct;11(10):1313-8. doi: 10.1016/j.cgh.2013.04.023. Epub 2013 Apr 29.

Reference Type RESULT
PMID: 23639600 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Exact Sciences 2010-A

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Stool Sample Collection Study
NCT06294873 RECRUITING